80 related articles for article (PubMed ID: 20587645)
1. Site-specific modification of anti-angiogenesis peptide HM-3 by polyethylene glycol molecular weight of 20 kDa.
Zhu B; Xu HM; Zhao L; Huang X; Zhang F
J Biochem; 2010 Sep; 148(3):341-7. PubMed ID: 20587645
[TBL] [Abstract][Full Text] [Related]
2. Studies of poly(ethylene glycol) modification of HM-3 polypeptides.
Zhou K; Zheng X; Xu HM; Zhang J; Chen Y; Xi T; Feng T
Bioconjug Chem; 2009 May; 20(5):932-6. PubMed ID: 19413309
[TBL] [Abstract][Full Text] [Related]
3. In vivo anti-tumor activity of polypeptide HM-3 modified by different polyethylene glycols (PEG).
Liu Z; Ren Y; Pan L; Xu HM
Int J Mol Sci; 2011; 12(4):2650-63. PubMed ID: 21731464
[TBL] [Abstract][Full Text] [Related]
4. In vivo pharmacokinetics, immunogenicity and mechanism of PEGylated antitumor polypeptide.
Liu Z; Li W; Xu HM; Huang X; Pan L; Ren Y; Yang Y; Li Y; Pu C; Zhang C
Curr Pharm Des; 2012; 18(12):1655-62. PubMed ID: 22283767
[TBL] [Abstract][Full Text] [Related]
5. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
6. Enhanced anti-angiogenesis and anti-tumor activity of endostatin by chemical modification with polyethylene glycol and low molecular weight heparin.
Tan H; Yang S; Liu C; Cao J; Mu G; Wang F
Biomed Pharmacother; 2012 Dec; 66(8):648-54. PubMed ID: 23122594
[TBL] [Abstract][Full Text] [Related]
7. Enhanced circulation half-life of site-specific PEGylated rhG-CSF: optimization of PEG molecular weight.
Zhai Y; Zhao Y; Lei J; Su Z; Ma G
J Biotechnol; 2009 Jul; 142(3-4):259-66. PubMed ID: 19497340
[TBL] [Abstract][Full Text] [Related]
8. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
Baker DP; Lin EY; Lin K; Pellegrini M; Petter RC; Chen LL; Arduini RM; Brickelmaier M; Wen D; Hess DM; Chen L; Grant D; Whitty A; Gill A; Lindner DJ; Pepinsky RB
Bioconjug Chem; 2006; 17(1):179-88. PubMed ID: 16417267
[TBL] [Abstract][Full Text] [Related]
9. An integrin αvβ3 antagonistic modified peptide inhibits tumor growth through inhibition of the ERK and AKT signaling pathways.
Hu L; Wang J; Wang Y; Xu H
Oncol Rep; 2016 Oct; 36(4):1953-62. PubMed ID: 27499314
[TBL] [Abstract][Full Text] [Related]
10. Preparation and stability of N-terminal mono-PEGylated recombinant human endostatin.
Nie Y; Zhang X; Wang X; Chen J
Bioconjug Chem; 2006; 17(4):995-9. PubMed ID: 16848407
[TBL] [Abstract][Full Text] [Related]
11. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
[TBL] [Abstract][Full Text] [Related]
12. Engineering an arginine catabolizing bioconjugate: Biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritidis.
Wang M; Basu A; Palm T; Hua J; Youngster S; Hwang L; Liu HC; Li X; Peng P; Zhang Y; Zhao H; Zhang Z; Longley C; Mehlig M; Borowski V; Sai P; Viswanathan M; Jang E; Petti G; Liu S; Yang K; Filpula D
Bioconjug Chem; 2006; 17(6):1447-59. PubMed ID: 17105223
[TBL] [Abstract][Full Text] [Related]
13. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
[TBL] [Abstract][Full Text] [Related]
15. Metalloprotease-specific poly(ethylene glycol) methyl ether-peptide-doxorubicin conjugate for targeting anticancer drug delivery based on angiogenesis.
Bae M; Cho S; Song J; Lee GY; Kim K; Yang J; Cho K; Kim SY; Byun Y
Drugs Exp Clin Res; 2003; 29(1):15-23. PubMed ID: 12866360
[TBL] [Abstract][Full Text] [Related]
16. Development of poly(ethylene glycol) conjugated lactoferrin for oral administration.
Nojima Y; Suzuki Y; Iguchi K; Shiga T; Iwata A; Fujimoto T; Yoshida K; Shimizu H; Takeuchi T; Sato A
Bioconjug Chem; 2008 Nov; 19(11):2253-9. PubMed ID: 18834167
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight polyethylene glycol improves survival in experimental sepsis.
Ackland GL; Gutierrez Del Arroyo A; Yao ST; Stephens RC; Dyson A; Klein NJ; Singer M; Gourine AV
Crit Care Med; 2010 Feb; 38(2):629-36. PubMed ID: 20009757
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice.
Kim WJ; Yockman JW; Jeong JH; Christensen LV; Lee M; Kim YH; Kim SW
J Control Release; 2006 Sep; 114(3):381-8. PubMed ID: 16884805
[TBL] [Abstract][Full Text] [Related]
19. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
Tsutsumi Y; Kihira T; Tsunoda S; Kamada H; Nakagawa S; Kaneda Y; Kanamori T; Mayumi T
J Pharmacol Exp Ther; 1996 Sep; 278(3):1006-11. PubMed ID: 8819479
[TBL] [Abstract][Full Text] [Related]
20. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
